Stop TB Partnership, Geneva, Switzerland.
The Task Force for Global Health/TEPHINET Guatemala Branch Office, Guatemala.
Gac Sanit. 2020 Mar-Apr;34(2):127-132. doi: 10.1016/j.gaceta.2019.02.010. Epub 2019 May 4.
To assess the impact of introducing Xpert as a follow-on test after smear microscopy on the total number pulmonary TB notifications.
Genexpert systems were installed in six departments across Guatemala, and Xpert was indicated as a follow-on test for people with smear-negative results. We analyzed notifications to national tuberculosis (TB) programmes (NTP) and the project's laboratory data to assess coverage of the intervention and case detection yield. Changes in quarterly TB notifications were analyzed using a simple pre/post comparison and a regression model controlling for secular notification trends. Using a mix of project and NTP data we estimated the theoretical yield of the intervention if testing coverage achieved 100%.
Over 18,000 smear-negative individuals were eligible for Xpert testing during the intervention period. Seven thousand, one hundred and ninety-three people (39.6% of those eligible) were tested on Xpert resulting in the detection of 199 people with smear-negative, Xpert positive results (2.8% positivity rate). In the year before testing began 1098 people with smear positive and 195 people with smear negative results were notified in the six intervention departments. During the intervention, smear-positive notification remained roughly stable (1090 individuals, 0.7%), but smear-negative notifications increased by 167 individuals (85.6%) to an all-time high of 362. After controlling for secular notifications trends over an eight-quarter pre-intervention period, combined pulmonary TB notifications (both smear positive and negative) were 19% higher than trend predictions. If Xpert testing coverage approached 100% of those eligible, we estimate there would have been a+41% increase in TB notifications.
We measured a large gain in pulmonary notifications through the introduction of Xpert testing alone. This indicates a large number of people with TB in Guatemala are seeking health care and being tested, yet are not diagnosed or treated because they lack bacteriological confirmation. Wider use of more sensitive TB diagnostics and/or improvements in the number of people clinically diagnosed with TB have the potential to significantly increase TB notifications in this setting, and potentially in other settings where a low proportion of pulmonary notifications are clinically diagnosed.
评估在痰涂片显微镜检查后引入 Xpert 作为后续检测对总的肺结核病例通报数的影响。
在危地马拉六个部门安装了 Genexpert 系统,并将 Xpert 作为痰涂片阴性结果者的后续检测。我们分析了国家结核病规划(NTP)和项目实验室的数据,以评估干预措施的覆盖范围和病例检出率。使用简单的前后比较和控制季节性通报趋势的回归模型分析了每季度结核病通报的变化。利用项目和 NTP 的混合数据,我们估计了如果检测覆盖率达到 100%,该干预措施的理论收益。
在干预期间,有 18000 多名痰涂片阴性的人符合 Xpert 检测条件。有 7193 人(符合条件者的 39.6%)接受了 Xpert 检测,发现了 199 例痰涂片阴性、Xpert 阳性的结果(阳性率 2.8%)。在开始检测之前的一年中,在六个干预部门中,有 1098 例痰涂片阳性和 195 例痰涂片阴性的人被通报。在干预期间,痰涂片阳性的通报数基本保持稳定(1090 人,0.7%),但痰涂片阴性的通报数增加了 167 人(85.6%),达到了历史最高水平 362 人。在控制了 8 个季度的干预前的季节性通报趋势后,合并的肺结核病例通报(包括痰涂片阳性和阴性)比趋势预测高出 19%。如果 Xpert 检测的覆盖率接近符合条件者的 100%,我们估计肺结核病例通报数将增加 41%。
我们仅通过引入 Xpert 检测就测量到了肺结核病例通报的大幅增加。这表明危地马拉有大量的结核病患者正在寻求医疗保健和接受检测,但由于缺乏细菌学确认,他们没有得到诊断或治疗。更广泛地使用更敏感的结核病诊断检测方法和/或增加临床上诊断为结核病的人数,有可能在这种情况下,以及在其他结核病病例中临床上诊断比例较低的情况下,显著增加结核病病例通报数。